newsfilter
← Latest News
GlobeNewswire·

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

First Phase 3 PDT study in patients with sBCC in the United States.Primary and secondary endpoints all highly statistically significant p<0.0001Correlates to data seen in Europe where sBCC is already incorporated in